Corient Private Wealth
KRTX

Corient Private Wealth’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Corient Private Wealth’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,504
Closed -$21.7M – 2389
2023
Q4 		$21.7M Buy
68,504
+19,912
+41% +$3.87M 0.04% 373
2023
Q3 		$8.22M Sell
48,592
-7,300
-13% -$1.37M 0.02% 521
2023
Q2 		$12.1M Buy
55,892
+702
+1% +$150K 0.03% 442
2023
Q1 		$10M Buy
+55,190
New +$10.6M 0.03% 434

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Corient Private Wealth's KRTX Position: Q1 2024 in Review

Corient Private Wealth sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 68,504 shares — an estimated $21.7M sold.

Corient Private Wealth first reported a position in KRTX in Q1 2023 and held it in 4 quarters. The position peaked at $21.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Corient Private Wealth reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Corient Private Wealth sold 68,504 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $21.7M.
  • Corient Private Wealth first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Corient Private Wealth's Karuna Therapeutics, Inc. Common Stock position peaked at $21.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Corient Private Wealth's 13F filing for Q1 2024, filed 9 May 2024.